Detect tumours changing cell type from RNA in the blood
Some cancers escape treatment by changing into a different kind of cell that the drug no longer affects. Tumour RNA in blood could show this shift months before a biopsy would.
Lineage plasticity (adenocarcinoma to small cell or neuroendocrine transformation in EGFR-mutant lung and prostate cancer) is a DNA-invisible resistance mechanism, usually diagnosed by biopsy late. Cell-free RNA and nucleosome footprinting can infer transcriptional state from plasma. The proposal is a plasma neuroendocrine transformation score monitored in patients at genetic risk (RB1 and TP53 loss) so that the switch to platinum-etoposide or a DLL3 bispecific is made early.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
Pages like this
not linked directly; found by shared links- PairingSequencing DLL3 engager and B7-H3 ADC in relapsed SCLC
Shares DLL3, Tarlatamab, Small-cell lung cancer.
- TrialDeLLphi-304
Shares DLL3, Tarlatamab, Small-cell lung cancer.
- TrialDeLLphi-305
Shares DLL3, Tarlatamab, Small-cell lung cancer.
- IdeaSubtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)
Shares DLL3, Tarlatamab, Small-cell lung cancer.
- IdeaGrow models from tumour cells in the blood when a biopsy is impossible
Shares Small-cell lung cancer, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Prostate cancer.
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- ProductRovalpituzumab tesirine
Shares DLL3, Tarlatamab, Small-cell lung cancer.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.